Low Density Lipoprotein (LDL) News and Research

RSS

VUMC doctors to begin statin drug screening for rare genetic variation

Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death.

29 Oct 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Soy protein can help lower blood lipids in healthy individuals

A new study published online in the European Journal of Clinical Nutrition shows that soy protein compared to dairy milk protein supplementation improves the lipid profile in healthy individuals.

21 Oct 2011

Gut bacteria shown to affect statin efficacy in some people

The team led by a Duke University scientist has identified three bile acids produced by gut bacteria that were evident in people who responded well to a common cholesterol-lowering drug called simvastatin. The finding, published Oct. 13, 2011, in PLoS One, demonstrates how gut bacteria can cause inherent differences in the way people digest, metabolize and benefit from substances such as drugs.

17 Oct 2011

Researchers identify gut bacteria bile acids linked to effectiveness of statin drugs in lowering cholesterol

Statins can be effective at lowering cholesterol, but they have a perplexing tendency to work for some people and not others. Gut bacteria may be the reason.

14 Oct 2011

Idera announces new data on novel gene-silencing oligonucleotide technology

Idera Pharmaceuticals, Inc. today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the Cell Symposium on Regulatory RNAs in Chicago, IL.

12 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Increasing levels of 'good' cholesterol reduces risk for heart attack and stroke among diabetics

Increasing levels of high-density lipoproteins, better known as HDL or "good" cholesterol, reduced the risk for heart attack and stroke among patients with diabetes. That's according to a new study appearing online today in The American Journal of Cardiology.

7 Oct 2011

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

The first patient has now been included in Karo Bio's phase III trial with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.

4 Oct 2011

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

28 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

AHA certifies walnuts as heart-healthy food

California Walnuts is proud to announce that the American Heart Association is now certifying walnuts as a heart-healthy food. The Heart-Check mark easily identifies foods that meet the nutritional standards set by the American Heart Association and provides consumers a quick and reliable way to identify heart-healthy foods.

23 Sep 2011

Karo Bio receives approval to initiate eprotirome phase III study in HeFH

Karo Bio AB has received approval from national regulatory authorities to start its phase III patient study with eprotirome, enabling the study to start as planned with an Investigators meeting in September.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

JCPT publishes 'The Need for Increased Utilization of Statins After Occlusive Stroke' study

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published a clinical study in the current issue of the Journal of Cardiovascular Pharmacology and Therapeutics (JCPT) titled "The Need for Increased Utilization of Statins After Occlusive Stroke."

15 Sep 2011

Aggressive medical management better than stenting for prevention of recurrent stroke

Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown. The investigators published the results in today's online first edition of the New England Journal of Medicine.

8 Sep 2011

Daily moderate drinking may decrease atherosclerosis

For the first time, new research shows that patterns of alcohol consumption - a drink or two every night, or several cocktails on Friday and Saturday nights only - may be more important in determining alcohol's influence on heart health than the total amount consumed.

8 Sep 2011

Computer-tailored nutrition education not effective in reducing fat intake

As lifestyles get busier and waistlines get bigger; many people are turning to online nutrition programs. In promotion of healthful nutrition behaviors, computer-tailored nutrition education has been identified as a promising health education strategy, especially in the promotion of lower fat intake.

7 Sep 2011

Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia

Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

2 Sep 2011

EAS/ESC develops new dyslipidaemias guidelines

Clinicians should aim for comprehensive lipid control using lifestyle as a first step and tailoring treatment to patients. Lifestyle interventions, including stopping smoking, improving diet, exercising sufficiently and moderate alcohol consumption, should be the crucial first step for managing lipids in all patients.

29 Aug 2011